Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1951 2
1952 5
1953 3
1954 9
1955 3
1956 2
1957 2
1958 2
1959 1
1963 1
1964 2
1965 6
1966 15
1967 7
1968 6
1969 17
1970 9
1971 15
1972 10
1973 16
1974 9
1975 15
1976 30
1977 33
1978 29
1979 33
1980 68
1981 37
1982 45
1983 51
1984 66
1985 37
1986 48
1987 30
1988 39
1989 65
1990 40
1991 59
1992 81
1993 60
1994 77
1995 64
1996 73
1997 107
1998 102
1999 109
2000 103
2001 142
2002 164
2003 166
2004 163
2005 220
2006 185
2007 210
2008 234
2009 206
2010 211
2011 239
2012 246
2013 237
2014 267
2015 272
2016 286
2017 350
2018 406
2019 485
2020 438
2021 454
2022 479
2023 551
2024 260

Text availability

Article attribute

Article type

Publication date

Search Results

7,590 results

Results by year

Filters applied: . Clear all
Page 1
Role of nutritional supplements in selected dermatological disorders: A review.
Sardana K, Sachdeva S. Sardana K, et al. J Cosmet Dermatol. 2022 Jan;21(1):85-98. doi: 10.1111/jocd.14436. Epub 2021 Sep 26. J Cosmet Dermatol. 2022. PMID: 34564936 Review.
RESULTS: While there are multiple publications on the use of nutritional supplements for amelioration of skin diseases, most of them are based on either associations or in vitro studies, but very few transcend the rigors of a clinical trial or the holey grail of a d …
RESULTS: While there are multiple publications on the use of nutritional supplements for amelioration of skin diseases, most of them are bas …
Systemic treatments for atopic dermatitis (eczema): Systematic review and network meta-analysis of randomized trials.
Chu AWL, Wong MM, Rayner DG, Guyatt GH, Díaz Martinez JP, Ceccacci R, Zhao IX, McMullen E, Srivastava A, Wang J, Wen A, Wang FC, Brignardello-Petersen R, Izcovich A, Oykhman P, Wheeler KE, Wang J, Spergel JM, Singh JA, Silverberg JI, Ong PY, O'Brien M, Martin SA, Lio PA, Lind ML, LeBovidge J, Kim E, Huynh J, Greenhawt M, Gardner DD, Frazier WT, Ellison K, Chen L, Capozza K, De Benedetto A, Boguniewicz M, Smith Begolka W, Asiniwasis RN, Schneider LC, Chu DK. Chu AWL, et al. J Allergy Clin Immunol. 2023 Dec;152(6):1470-1492. doi: 10.1016/j.jaci.2023.08.029. Epub 2023 Sep 9. J Allergy Clin Immunol. 2023. PMID: 37678577 Free article.
METHODS: For the 2023 American Academy of Allergy, Asthma & Immunology and American College of Allergy, Asthma, and Immunology Joint Task Force on Practice Parameters AD guidelines, we searched MEDLINE, EMBASE, CENTRAL, Web of Science, and GREAT databases from inception to No …
METHODS: For the 2023 American Academy of Allergy, Asthma & Immunology and American College of Allergy, Asthma, and Immunology Joint Tas …
Topical treatments for atopic dermatitis (eczema): Systematic review and network meta-analysis of randomized trials.
Chu DK, Chu AWL, Rayner DG, Guyatt GH, Yepes-Nuñez JJ, Gomez-Escobar L, Pérez-Herrera LC, Díaz Martinez JP, Brignardello-Petersen R, Sadeghirad B, Wong MM, Ceccacci R, Zhao IX, Basmaji J, MacDonald M, Chu X, Islam N, Gao Y, Izcovich A, Asiniwasis RN, Boguniewicz M, De Benedetto A, Capozza K, Chen L, Ellison K, Frazier WT, Greenhawt M, Huynh J, LeBovidge J, Lio PA, Martin SA, O'Brien M, Ong PY, Silverberg JI, Spergel JM, Smith Begolka W, Wang J, Wheeler KE, Gardner DD, Schneider L. Chu DK, et al. J Allergy Clin Immunol. 2023 Dec;152(6):1493-1519. doi: 10.1016/j.jaci.2023.08.030. Epub 2023 Sep 9. J Allergy Clin Immunol. 2023. PMID: 37678572 Free article.
METHODS: For the 2023 American Academy of Allergy, Asthma & Immunology and American College of Allergy, Asthma, and Immunology Joint Task Force on Practice Parameters AD guidelines, we searched MEDLINE, EMBASE, CENTRAL, CINAHL, LILACS, ICTRP, and GREAT databases to September …
METHODS: For the 2023 American Academy of Allergy, Asthma & Immunology and American College of Allergy, Asthma, and Immunology Joint Tas …
Anti-TSLP antibodies: Targeting a master regulator of type 2 immune responses.
Nakajima S, Kabata H, Kabashima K, Asano K. Nakajima S, et al. Allergol Int. 2020 Apr;69(2):197-203. doi: 10.1016/j.alit.2020.01.001. Epub 2020 Jan 21. Allergol Int. 2020. PMID: 31974038 Free article. Review.
Tezepelumab (AMG-157/MEDI9929) is a human anti-TSLP antibody that prevents TSLP-TSLPR interactions. A phase 2 trial for moderate to severe AD showed that a greater but not statistically significant percentage of tezepelumab-treated patients showed clinical improveme …
Tezepelumab (AMG-157/MEDI9929) is a human anti-TSLP antibody that prevents TSLP-TSLPR interactions. A phase 2 trial for moderate to s …
Comparative Efficacy and Safety of Monoclonal Antibodies and Janus Kinase Inhibitors in Moderate-to-severe Atopic Dermatitis: A Systematic Review and Meta-analysis.
Sedeh FB, Henning MAS, Jemec GBE, Ibler KS. Sedeh FB, et al. Acta Derm Venereol. 2022 Aug 24;102:adv00764. doi: 10.2340/actadv.v102.2075. Acta Derm Venereol. 2022. PMID: 35818735 Free PMC article.
A systematic review following Preferred Reporting Items for Systemic Reviews and Meta-Analyses (PRISMA) guidelines was performed using Medline, EMBASE and Cochrane library. All randomized controlled trials investigating the efficacy of systemic treatments for moderate-to-s …
A systematic review following Preferred Reporting Items for Systemic Reviews and Meta-Analyses (PRISMA) guidelines was performed using Medli …
Tralokinumab: First Approval.
Duggan S. Duggan S. Drugs. 2021 Sep;81(14):1657-1663. doi: 10.1007/s40265-021-01583-1. Drugs. 2021. PMID: 34406631 Free PMC article. Review.
An Overview of PDE4 Inhibitors in Clinical Trials: 2010 to Early 2022.
Crocetti L, Floresta G, Cilibrizzi A, Giovannoni MP. Crocetti L, et al. Molecules. 2022 Aug 4;27(15):4964. doi: 10.3390/molecules27154964. Molecules. 2022. PMID: 35956914 Free PMC article. Review.
Several scientific advancements, by both academia and pharmaceutical companies, have enabled the identification of many synthetic ligands for this target, along with the acquisition of precise information on biological requirements and linked therapeutic opportunities. The transi …
Several scientific advancements, by both academia and pharmaceutical companies, have enabled the identification of many synthetic ligands fo …
Efficacy and Safety of Upadacitinib in Patients With Moderate to Severe Atopic Dermatitis: Analysis of Follow-up Data From the Measure Up 1 and Measure Up 2 Randomized Clinical Trials.
Simpson EL, Papp KA, Blauvelt A, Chu CY, Hong HC, Katoh N, Calimlim BM, Thyssen JP, Chiou AS, Bissonnette R, Stein Gold LF, Wegzyn C, Hu X, Liu M, Liu J, Tenorio AR, Chu AD, Guttman-Yassky E. Simpson EL, et al. JAMA Dermatol. 2022 Apr 1;158(4):404-413. doi: 10.1001/jamadermatol.2022.0029. JAMA Dermatol. 2022. PMID: 35262646 Free PMC article.
DESIGN, SETTING, AND PARTICIPANTS: Measure Up 1 and Measure Up 2 are ongoing double-blind, placebo-controlled, replicate phase 3 randomized clinical trials that include adults and adolescents with moderate to severe atopic dermatitis at 151 and 154 centers, respecti …
DESIGN, SETTING, AND PARTICIPANTS: Measure Up 1 and Measure Up 2 are ongoing double-blind, placebo-controlled, replicate phase 3 randomiz …
Abrocitinib efficacy and safety in patients with moderate-to-severe atopic dermatitis: Results from phase 3 studies, including the long-term extension JADE EXTEND study.
Reich K, Silverberg JI, Papp KA, Deleuran M, Katoh N, Strober B, Beck LA, de Bruin-Weller M, Werfel T, Zhang F, Biswas P, DiBonaventura MD, Chan G, Johnson S, Farooqui SA, Kerkmann U, Clibborn C. Reich K, et al. J Eur Acad Dermatol Venereol. 2023 Oct;37(10):2056-2066. doi: 10.1111/jdv.19280. Epub 2023 Jul 11. J Eur Acad Dermatol Venereol. 2023. PMID: 37335885
Systematic review of treatments for atopic eczema.
Hoare C, Li Wan Po A, Williams H. Hoare C, et al. Health Technol Assess. 2000;4(37):1-191. Health Technol Assess. 2000. PMID: 11134919 Free PMC article. Review.
OBJECTIVES: The objectives of this scoping review are two-fold. To produce an up-to-date coverage 'map' of randomised controlled trials (RCTs) of treatments of atopic eczema. ...QUALITY ASSESSMENT: The quality assessment of retrieved RCTs included an assessment of: a clear …
OBJECTIVES: The objectives of this scoping review are two-fold. To produce an up-to-date coverage 'map' of randomised controlled tria …
7,590 results